Elena Pentsova, MD
Carboxyamidotriazole orotate (CTO) in combination with temozolomide (Temodar), with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma (GBM) or anaplastic gliomas.
of CTO, the next lower dose level.
Omuro A, Beal K, McNeill K, et al. Multicenter phase ib trial of carboxyamidotriazole orotate and temozolomide for recurrent and newly diagnosed glioblastoma and other anaplastic gliomas [published online April 23, 2018]. J Clin Oncol. 2018 Apr 23:JCO2017769992. doi: 10.1200/JCO.2017.76.9992.
... to read the full story